Sight Sciences (SGHT) Aktievy
Sight Sciences, Inc. är ett medicintekniskt företag som fokuserar på utveckling och kommersialisering av kirurgiska och icke-kirurgiska teknologier för behandling av ögonsjukdomar i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 1/6 |
| Framtida tillväxt | 0/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
SGHT Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sight Sciences, Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$5.32 |
| 52 veckors högsta | US$9.24 |
| 52 veckors lägsta | US$3.11 |
| Beta | 2.38 |
| 1 månads förändring | 10.37% |
| 3 månaders förändring | 54.20% |
| 1 års förändring | 56.01% |
| 3 års förändring | -31.71% |
| 5 års förändring | -83.73% |
| Förändring sedan börsintroduktionen | -84.12% |
Senaste nyheter och uppdateringar
Uppdatering av berättelse • Jul 01
SGHT: Sector Strength And Dry Eye Outlook Will Support Measured Repricing
Analysts lifted their price target on Sight Sciences to $5.15 from $4.35, citing updated medical technology sector models after Q1 reports and a view that sector fundamentals remain solid. Analyst Commentary Recent commentary on Sight Sciences reflects a mixed stance, with some analysts adjusting their models after the latest Q1 updates while keeping a neutral overall view on the stock.
Uppdatering av berättelse • Jun 17
SGHT: Sector Support And Dry Eye Execution Will Drive Future Upside
Analysts have increased their price target on Sight Sciences stock to $5.15 from $4.35, citing refreshed medical technology sector models after Q1 updates and a view that broader fundamentals in the space remain solid. Analyst Commentary on Sight Sciences Recent research commentary on Sight Sciences centers on refreshed models following Q1 updates and a reassessment of where the stock fits within the broader medical technology group.Uppdatering av berättelse • Jun 02
SGHT: Dry Eye Execution And TearCare Adoption Will Support Future Upside
Analysts have maintained Sight Sciences' fair value target at $12.00 while refining underlying assumptions such as discount rate and margin forecasts. Recent Street research highlights sector models being refreshed and mixed segment trends as key drivers of the updated $5.15 Citi price target and other revised targets across the stock.Recent updates
Uppdatering av berättelse • Jul 01
SGHT: Sector Strength And Dry Eye Outlook Will Support Measured Repricing
Analysts lifted their price target on Sight Sciences to $5.15 from $4.35, citing updated medical technology sector models after Q1 reports and a view that sector fundamentals remain solid. Analyst Commentary Recent commentary on Sight Sciences reflects a mixed stance, with some analysts adjusting their models after the latest Q1 updates while keeping a neutral overall view on the stock.Uppdatering av berättelse • Jun 17
SGHT: Sector Support And Dry Eye Execution Will Drive Future Upside
Analysts have increased their price target on Sight Sciences stock to $5.15 from $4.35, citing refreshed medical technology sector models after Q1 updates and a view that broader fundamentals in the space remain solid. Analyst Commentary on Sight Sciences Recent research commentary on Sight Sciences centers on refreshed models following Q1 updates and a reassessment of where the stock fits within the broader medical technology group.Uppdatering av berättelse • Jun 02
SGHT: Dry Eye Execution And TearCare Adoption Will Support Future Upside
Analysts have maintained Sight Sciences' fair value target at $12.00 while refining underlying assumptions such as discount rate and margin forecasts. Recent Street research highlights sector models being refreshed and mixed segment trends as key drivers of the updated $5.15 Citi price target and other revised targets across the stock.Uppdatering av berättelse • May 10
SGHT: Weaker Glaucoma Trends Will Limit Rerating Despite Solid Dry Eye Momentum
Analysts have trimmed their price targets for Sight Sciences, with one key target moving from $6.50 to $5 and another from $12 to $11. These revisions reflect updated views on a mix of steady sector fundamentals, solid Dry Eye performance, and softer Surgical Glaucoma trends.Uppdatering av berättelse • Apr 23
SGHT: Dry Eye Franchise And TearCare Adoption Will Drive Future Upside
The blended analyst price target for Sight Sciences has moved modestly lower to $11 from $12, as analysts balance pressure in Surgical Glaucoma against steady TearCare adoption, sector wide target resets, and updated assumptions for the discount rate, revenue growth, profit margin, and future P/E. Analyst Commentary Recent research updates show a wide range of views on Sight Sciences, with price targets clustered between the mid single digits and low double digits and ratings spanning Neutral to Buy.Uppdatering av berättelse • Apr 08
SGHT: TearCare And Dry Eye Adoption Will Support Future Upside Potential
Narrative Update on Sight Sciences Analysts have adjusted price targets for Sight Sciences into a range of $5 to $11, reflecting updated views on the balance between softer Surgical Glaucoma trends and stronger TearCare and Dry Eye performance. Overall sector fundamentals are described as healthy.Uppdatering av berättelse • Mar 25
SGHT: Dry Eye Momentum Will Support Stronger Outlook Than Surgical Glaucoma
Analysts have trimmed their average price target on Sight Sciences by $1.00, reflecting updated assumptions around growth, margins and sector risk after recent research highlighted mixed trends between TearCare strength and softer Surgical Glaucoma performance. Analyst Commentary Street research on Sight Sciences has converged around a more cautious but still constructive stance, with price targets adjusted to reflect mixed trends between TearCare strength and softer Surgical Glaucoma performance.Uppdatering av berättelse • Mar 11
SGHT: TearCare Momentum Will Support Rerating Despite Surgical Glaucoma Concerns
The updated analyst price target for Sight Sciences moves to $6.50, reflecting a blended view where some analysts trimmed targets, others raised them toward $8 to $11, and recent feedback on TearCare and mixed segment trends shaped modest adjustments to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research on Sight Sciences gives you a mixed picture, with some analysts more constructive on TearCare adoption and others turning more cautious on execution and growth in the surgical glaucoma segment.Uppdatering av berättelse • Feb 24
SGHT: Longer Term Glaucoma Data Will Support Stronger Outlook For Therapy
Analysts have maintained their $12.00 price target on Sight Sciences, noting that minor adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions largely offset one another. What's in the News Sight Sciences issued new earnings guidance for the fourth quarter of 2025, with total revenue expected between $20.3 million and $20.4 million, described as a 7% increase at the midpoint compared to the prior year period (Key Developments).Uppdatering av berättelse • Feb 09
SGHT: Longer Term Glaucoma Data Will Support Stronger Outlook For Therapy
Analysts have kept their price target for Sight Sciences steady at US$12.00, citing updated assumptions that include slightly higher discount and P/E expectations, along with adjusted revenue growth and profit margin forecasts. What's in the News Sight Sciences issued earnings guidance for the fourth quarter of 2025, with total revenue projected between US$20.3 million and US$20.4 million.Uppdatering av berättelse • Jan 26
SGHT: Fair Outlook Balances Guidance Revision With Leadership And Margin Assumptions
Analysts have lifted their price target for Sight Sciences from US$3.60 to US$6.00, pointing to updated assumptions around revenue growth, profit margins, discount rate and a higher future P/E multiple as key drivers of the change. What's in the News Sight Sciences issued earnings guidance for the fourth quarter of 2025, with total revenue expected between US$20.3 million and US$20.4 million, described as a 7% increase at the midpoint compared to the prior year period (Corporate Guidance).Analysartikel • Jan 21
Sight Sciences, Inc.'s (NASDAQ:SGHT) 26% Share Price Plunge Could Signal Some Risk
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has softened a substantial 26% over the previous 30 days, handing...
Uppdatering av berättelse • Jan 11
SGHT: Final Medicare Coverage Will Support Dry Eye Upside Potential
Analysts have lifted their price target on Sight Sciences from $7.85 to $9.35, citing recent Medicare coverage decisions for the TearCare dry eye disease treatment system as a key support for their updated view. Analyst Commentary Bullish Takeaways Bullish analysts view the finalized Medicare coverage policies for TearCare as a key support for the higher price targets, since clearer reimbursement can make revenue visibility easier to model.Seeking Alpha • Dec 31
Sight Sciences: Improving Medicare Coverage Drives Eye-Popping Price Surge
Summary Sight Sciences surged over 100% after two major Medicare contractors approved coverage for its TearCare dry eye treatment. Positive reimbursement decisions for TearCare open up a sizable market opportunity ($400 ASP and multiple millions of treatable patients) that was severely limited on a self-pay basis. OMNI is still the much larger business today, and while the company secured a positive reimbursement decision, market penetration may be limited or slowed by the company's tight finances. SGHT faces significant liquidity risks, and I believe the company should look to raise cash in 2026, particularly in light of the recent share price surge. I see fair value near $9.50/share, but further upside depends on sales execution and additional coverage wins. Read the full article on Seeking AlphaUppdatering av berättelse • Dec 26
SGHT: Medicare Coverage Expansion Will Drive Stronger Outlook For Dry Eye Therapy
Analysts have raised their price target on Sight Sciences from $5 to $7 per share, citing recently finalized Medicare coverage policies for the TearCare dry eye treatment system as a key potential driver of outperformance. Analyst Commentary Bullish analysts highlight that the higher price target reflects growing confidence in Sight Sciences' ability to monetize new Medicare coverage for its TearCare dry eye treatment system.Uppdatering av berättelse • Dec 11
SGHT: Final Medicare Coverage Will Shape Dry Eye Outlook And Execution Risks
Analysts have modestly raised their price target on Sight Sciences from approximately $6.08 to about $7.85 per share, citing improved fair value estimates and expectations that finalized Medicare coverage for the TearCare dry eye treatment system could drive future outperformance. Analyst Commentary With the recent coverage decisions for TearCare by key Medicare administrative contractors, Street research has become more constructive on Sight Sciences' medium term outlook, though some execution risks remain in focus.Uppdatering av berättelse • Nov 27
SGHT: Broader Medicare Coverage Will Increase Risks For Execution Going Forward
Analysts have raised their price target for Sight Sciences from $5.00 to $7.00 per share. They cite broader Medicare coverage for its Dry Eye Disease treatment system as a key factor supporting the positive outlook.Analysartikel • Nov 13
Sight Sciences (NASDAQ:SGHT) Has Debt But No Earnings; Should You Worry?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Uppdatering av berättelse • Nov 08
SGHT: Higher Medicare Access Will Increase Competitive Execution Risks Ahead
Analysts have raised their price target for Sight Sciences from approximately $4.42 to $5.08, citing expanded Medicare coverage and stronger growth expectations across key financial metrics. Analyst Commentary Bullish Takeaways Bullish analysts highlighted the substantial increase in the price target following newly finalized Medicare coverage for the TearCare system.Analysartikel • Oct 18
Market Participants Recognise Sight Sciences, Inc.'s (NASDAQ:SGHT) Revenues Pushing Shares 37% Higher
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has done very well over the last month, posting an excellent gain...Analysartikel • Aug 09
Does Sight Sciences (NASDAQ:SGHT) Have A Healthy Balance Sheet?
NasdaqGS:SGHT 1 Year Share Price vs Fair Value Explore Sight Sciences's Fair Values from the Community and select yours...Uppdatering av berättelse • Aug 08
Expanding Healthcare Access And Chronic Eye Disease Trends Will Boost Minimally Invasive Procedures
Sight Sciences' consensus price target has increased, primarily reflecting improved revenue growth forecasts, with fair value rising from $3.93 to $4.27. What's in the News Raised full-year 2025 revenue guidance to $72–76 million (still a 5–10% decline vs.Analysartikel • May 14
Sight Sciences, Inc. (NASDAQ:SGHT) Surges 44% Yet Its Low P/S Is No Reason For Excitement
Sight Sciences, Inc. ( NASDAQ:SGHT ) shareholders would be excited to see that the share price has had a great month...
Ny berättelse • Apr 04
OMNIEdge And TearCare Will Transform MIGS Treatments
Strategic initiatives, such as the OMNIEdge launch and positive reimbursement for TearCare, aim to capture market share and improve revenue and margins.Analysartikel • Mar 30
Sight Sciences, Inc. (NASDAQ:SGHT) Looks Inexpensive But Perhaps Not Attractive Enough
Sight Sciences, Inc.'s ( NASDAQ:SGHT ) price-to-sales (or "P/S") ratio of 1.6x might make it look like a buy right now...Analysartikel • Jan 17
Is Sight Sciences (NASDAQ:SGHT) Using Debt Sensibly?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analysartikel • Nov 13
Sight Sciences, Inc. (NASDAQ:SGHT) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
The Sight Sciences, Inc. ( NASDAQ:SGHT ) share price has fared very poorly over the last month, falling by a...Aktieägarnas avkastning
| SGHT | US Medical Equipment | US Marknad | |
|---|---|---|---|
| 7D | -2.4% | -1.5% | 0.6% |
| 1Y | 56.0% | -19.9% | 19.5% |
Avkastning vs industri: SGHT översteg US Medical Equipment branschen som gav -19.9 % under det senaste året.
Avkastning vs Marknaden: SGHT översteg US marknaden som gav 19.5 % under det senaste året.
Prisvolatilitet
| SGHT volatility | |
|---|---|
| SGHT Average Weekly Movement | 10.7% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabil aktiekurs: SGHT har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: SGHT s veckovolatilitet ( 11% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2010 | 186 | Paul Badawi | www.sightsciences.com |
Sight Sciences, Inc. är ett medicintekniskt företag som fokuserar på utveckling och kommersialisering av kirurgiska och icke-kirurgiska teknologier för behandling av ögonsjukdomar i USA. Företaget är verksamt inom två segment, Surgical Glaucoma och Dry Eye. Företaget erbjuder OMNI, en produktfamilj med kirurgiska system, såsom OMNI Ergo för kateterisering och transluminal viskodilatation av Schlemms kanal och skärning av trabekelverket för att minska det intraokulära trycket hos vuxna patienter med öppenvinkelglaukom; och OMNI EDGE, en implantatfri och minimalinvasiv teknologi för glaukomkirurgi.
Sight Sciences, Inc. Sammanfattning av grunderna
| SGHT grundläggande statistik | |
|---|---|
| Börsvärde | US$286.20m |
| Vinst(TTM) | -US$37.25m |
| Intäkter(TTM) | US$79.55m |
3.6x
P/S-förhållande-7.8x
P/E-förhållandeÄr SGHT övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| SGHT resultaträkning (TTM) | |
|---|---|
| Intäkter | US$79.55m |
| Kostnad för intäkter | US$11.00m |
| Bruttovinst | US$68.55m |
| Övriga kostnader | US$105.80m |
| Intäkter | -US$37.25m |
Senast redovisade vinst
Mar 31, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.68 |
| Bruttomarginal | 86.17% |
| Nettovinstmarginal | -46.83% |
| Skuld/egenkapitalförhållande | 75.2% |
Hur har SGHT utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/07/10 22:51 |
| Aktiekurs vid dagens slut | 2026/07/10 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Sight Sciences, Inc. bevakas av 10 analytiker. 6 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Craig Bijou | BofA Global Research |
| Joanne Wuensch | Citigroup Inc |
| Frank Takkinen | Lake Street Capital Markets, LLC |